Merck (MSD outside North America) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences , through a subsidiary, for $36.00 per each share in cash or for a total equity price of nearly $1.35bn.
A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.
The lead candidate of the company bomedemstat (IMG-7289) is an investigational, orally available inhibitor of lysine-specific demethylase 1 (LSD1).
At present, bomedemstat is being analysed in various Phase II clinical trials to treat myelofibrosis, essential thrombocythemia and polycythemia vera, apart from various other indications.
The Imago takeover will extend the growing haematology portfolio of Merck .
Merck president and CEO Robert Davis said: “We continue to invest in our pipeline with a focus on applying our unique capabilities to unlock the value of breakthrough science for the patients we serve.
“This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of haematology.”
As per the deal, the acquisition subsidiary of Merck will be merged into Imago following closing.
The acquisition is anticipated to conclude in the first quarter of next year.
Imago BioSciences founder and CEO Dr Hugh Rienhoff said: “This agreement leverages Merck’s industry-leading clinical development expertise to maximise the therapeutic potential of bomedemstat while providing important value for shareholders.”
In October this year, Merck reported worldwide sales of $15bn in the third quarter (Q3) of 2022 as against $13.15bn in the year-ago quarter, indicating a rise of 14%.
Source: pharmaceutical-technology.com
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.
